Cover Image

Neoadjuvant epirubicin, gemcitabine and docetaxel for primary breast cancer: long-term survival data and major prognostic factors based on two consecutive neoadjuvant phase I/II trials

We previously reported primary endpoints of two consecutive phase I/II trials, evaluating different schedules of neoadjuvant epirubicin (E), gemcitabine (G) and docetaxel (Doc) for primary breast cancer (PBC). Here, we report mature survival data and prognostic factors. One hundred fifty-one patient...

Full description

Saved in:
Bibliographic Details
Main Authors: Marmé, Frederik (Author) , Aigner, Julia (Author) , Lorenzo Bermejo, Justo (Author) , Sinn, Peter (Author) , Sohn, Christof (Author) , Jäger, Dirk (Author) , Schneeweiss, Andreas (Author)
Format: Article (Journal)
Language:English
Published: 7 February 2013
In: International journal of cancer
Year: 2013, Volume: 133, Issue: 4, Pages: 1006-1015
ISSN:1097-0215
DOI:10.1002/ijc.28094
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1002/ijc.28094
Verlag, lizenzpflichtig, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.28094
Get full text
Author Notes:Frederik Marmé, Julia Aigner, Justo Lorenzo Bermejo, Peter Sinn, Christof Sohn, Dirk Jäger and Andreas Schneeweiss
Description
Summary:We previously reported primary endpoints of two consecutive phase I/II trials, evaluating different schedules of neoadjuvant epirubicin (E), gemcitabine (G) and docetaxel (Doc) for primary breast cancer (PBC). Here, we report mature survival data and prognostic factors. One hundred fifty-one patients were recruited into two consecutive phase I/II trials of neoadjuvant chemotherapy for T2-4 N0-2 M0 PBC. Patients received six cycles of G/E/Doc every 3 weeks with G repeated on d8 (GEDoc, n = 84) or five cycles of G/E followed by four cycles of Doc all given every two weeks (GEsDoc, n = 67). Prognostic factors were investigated using univariate and multivariate analyses. No survival differences by treatment were found. Among reported predictive factors for pathologic complete response (pCR), oestrogen receptor (ER) status was the only relevant factor in the multivariate analysis. Unexpectedly, pCR resulted in poorer survival (univariate HR for overall survival [OS] 3.11, p = 0.007). Multivariate analyses identified molecular subtype and tumour size as the most relevant prognostic factors for OS. HER2-receptor status and the CPS-EG score (Mittendorf et al., J Clin Oncol 2011;29:1956-62), based on clinical and pathological stage, ER-status and tumour grade, were particularly relevant in disease-free survival. Our findings cast doubt on the reliability of pCR as single marker for prognosis of this unselected breast cancer cohort, with an abundance of luminal subtypes. These results underline the significance of additional molecular characteristics for breast cancer survival.
Item Description:Gesehen am 23.06.2021
Physical Description:Online Resource
ISSN:1097-0215
DOI:10.1002/ijc.28094

Similar Items